publication venue for
- A loss-of-function polymorphism in ATG16L1 compromises therapeutic outcome in head and neck carcinoma patients.. 11. 2022
- Tumor-associated macrophages promote intratumoral conversion of conventional CD4+ T cells into regulatory T cells via PD-1 signalling.. 11. 2022
- Intratumoral T-cell repertoires in DNA mismatch repair-proficient and -deficient colon tumors containing high or low numbers of tumor-infiltrating lymphocytes.. 11. 2022
- LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells.. 10. 2021
- Low-dose CDK4/6 inhibitors induce presentation of pathway specific MHC ligands as potential targets for cancer immunotherapy.. 10. 2021
- A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma.. 10. 2021
- A novel multimeric IL15/IL15Rα-Fc complex to enhance cancer immunotherapy.. 10. 2021
- TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients.. 10. 2021
- Quantitative assessment of tumor-infiltrating lymphocytes in mismatch repair proficient colon cancer.. 9. 2020
- Converging focal radiation and immunotherapy in a preclinical model of triple negative breast cancer: contribution of VISTA blockade.. 9. 2020
- Targeting ubiquitin protein ligase E3 component N-recognin 5 in cancer cells induces a CD8+ T cell mediated immune response.. 9. 2020
- PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models.. 9. 2020
- Blockade of Stat3 oncogene addiction induces cellular senescence and reveals a cell-nonautonomous activity suitable for cancer immunotherapy.. 9. 2020
- Organotypic tumor slice cultures provide a versatile platform for immuno-oncology and drug discovery.. 8. 2019
- Calreticulin arms NK cells against leukemia.. 9. 2019
- Apoptotic caspases inhibit abscopal responses to radiation and identify a new prognostic biomarker for breast cancer patients.. 8. 2019
- Apoptotic caspases cut down the immunogenicity of radiation.. 8. 2019
- Targeting the C-terminus of galectin-9 induces mesothelioma apoptosis and M2 macrophage depletion.. 8. 2019
- Depleting T regulatory cells by targeting intracellular Foxp3 with a TCR mimic antibody.. 8. 2019
- Tumor lysis with LTX-401 creates anticancer immunity.. 8. 2019
- Metabolic enzymes expressed by cancer cells impact the immune infiltrate.. 8. 2019
- Potentiating vascular-targeted photodynamic therapy through CSF-1R modulation of myeloid cells in a preclinical model of prostate cancer.. 8. 2019
- Cancer vaccines: designing artificial synthetic long peptides to improve presentation of class I and class II T cell epitopes by dendritic cells.. 8. 2019
- Anticancer effects of anti-CD47 immunotherapy in vivo.. 8. 2018
- Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation,in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model.. 8. 2018
- Tumor mutational burden is a determinant of immune-mediated survival in breast cancer.. 7. 2018
- PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab.. 7. 2018
- Immune effectors responsible for the elimination of hyperploid cancer cells.. 7. 2018
- Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: Results of a phase I study.. 7. 2018
- CD4+ Th1 to the rescue in HER-2+ breast cancer.. 8. 2018
- Potential immune priming of the tumor microenvironment with FOLFOX chemotherapy in locally advanced rectal cancer.. 7. 2018
- Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms.. 7. 2018
- TNFR2/BIRC3-TRAF1 signaling pathway as a novel NK cell immune checkpoint in cancer.. 7. 2017
- Langerhans-type dendritic cells electroporated with TRP-2 mRNA stimulate cellular immunity against melanoma: Results of a phase I vaccine trial.. 7. 2017
- Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival.. 6. 2017
- Mammary tumor-derived CCL2 enhances pro-metastatic systemic inflammation through upregulation of IL1β in tumor-associated macrophages.. 6. 2017
- TREX1 dictates the immune fate of irradiated cancer cells.. 6. 2017
- IL-18 receptor marks functional CD8+ T cells in non-small cell lung cancer.. 6. 2017
- Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2.. 6. 2017
- Downregulation of PTP1B and TC-PTP phosphatases potentiate dendritic cell-based immunotherapy through IL-12/IFNγ signaling.. 6. 2017
- Novel immune checkpoint blocker to treat Merkel cell carcinoma.. 6. 2017
- Maternal microchimerism is prevalent in cord blood in memory T cells and other cell subsets, and persists post-transplant.. 6. 2017
- Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody.. 6. 2017
- Results of a phase I-II study of adjuvant concurrent carboplatin and accelerated radiotherapy for triple negative breast cancer.. 6. 2016
- CAR T-cell intrinsic PD-1 checkpoint blockade: A two-in-one approach for solid tumor immunotherapy.. 6. 2016
- An immunogenic WT1-derived peptide that induces T cell response in the context of HLA-A*02:01 and HLA-A*24:02 molecules.. 6. 2016
- Cytokine profiling of tumor interstitial fluid of the breast and its relationship with lymphocyte infiltration and clinicopathological characteristics.. 5. 2016
- The ratio of CD8+/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma in situ.. 5. 2016
- Mechanisms of leukemia resistance to antibody dependent cellular cytotoxicity.. 5. 2016
- Addition of anti-estrogen therapy to anti-HER2 dendritic cell vaccination improves regional nodal immune response and pathologic complete response rate in patients with ERpos/HER2pos early breast cancer.. 6. 2016
- Exosome-driven transfer of tumor-associated Pioneer Translation Products (TA-PTPs) for the MHC class I cross-presentation pathway.. 5. 2016
- IL-32 induces indoleamine 2,3-dioxygenase+CD1c+ dendritic cells and indoleamine 2,3-dioxygenase+CD163+ macrophages: Relevance to mycosis fungoides progression.. 6. 2016
- Successful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumors.. 5. 2016
- Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy.. 5. 2016
- Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy.. 5. 2016
- Inhibition of formyl peptide receptor 1 reduces the efficacy of anticancer chemotherapy against carcinogen-induced breast cancer.. 5. 2016
- STAT3 inhibition for cancer therapy: Cell-autonomous effects only?. 5. 2016
- First oncolytic virus approved for melanoma immunotherapy.. 5. 2015
- Doubling the blockade for melanoma immunotherapy.. 5. 2015
- Targeting abnormal ER stress responses in tumors: A new approach to cancer immunotherapy.. 5. 2015
- Improvement of immunogenic chemotherapy by STAT3 inhibition.. 5. 2015
- Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC).. 4. 2015
- Autocrine signaling of type 1 interferons in successful anticancer chemotherapy.. 4. 2015
- Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question mark.. 4. 2015
- Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-GD2 immunotherapy and isotretinoin: a prospective Phase II study.. 4. 2015
- Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody.. 4. 2015
- Genetics and immunology: reinvigorated.. 4. 2015
- Anti-proliferative and pro-apoptotic activity of GD2 ganglioside-specific monoclonal antibody 3F8 in human melanoma cells.. 4. 2015
- Trial watch: Naked and vectored DNA-based anticancer vaccines.. 4. 2015
- The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers.. 4. 2015
- Immunotherapy of hematological cancers: PD-1 blockade for the treatment of Hodgkin's lymphoma.. 4. 2015
- Immune independent crosstalk between lymphoma and myeloid suppressor CD14+HLA-DRlow/neg monocytes mediates chemotherapy resistance.. 4. 2015
- IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo.. 4. 2015
- Novel immune checkpoint blocker approved for the treatment of advanced melanoma.. 3. 2014
- The tumor immune microenvironment in octogenarians with stage I non-small cell lung cancer.. 3. 2014
- Vitamin B6 improves the immunogenicity of cisplatin-induced cell death.. 3. 2014
- Trial Watch: Toll-like receptor agonists in oncological indications.. 3. 2014
- Trial watch: Immunostimulatory cytokines in cancer therapy.. 3. 2014
- Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death.. 3. 2014
- Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set.. 3. 2014
- Is tumor (R)ejection by the immune system the "5th R" of radiobiology?. 3. 2014
- Detection of cancer/testis antigens as a diagnostic tool in routine pathology practice.. 3. 2014
- Novel insights into the mechanism of action of lenalidomide.. 3. 2014
- Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy.. 3. 2014
- Why should we need the gut microbiota to respond to cancer therapies?. 3. 2014
- Chemokines and chemokine receptors required for optimal responses to anticancer chemotherapy.. 3. 2014
- Immunological effects of chemotherapy in spontaneous breast cancers.. 2. 2013
- Immune effectors required for the therapeutic activity of vorinostat.. 2. 2013
- Immunogenic cell death in radiation therapy.. 2. 2013
- The TLR7 agonist imiquimod as an adjuvant for radiotherapy-elicited in situ vaccination against breast cancer.. 2. 2013
- Current trends of anticancer immunochemotherapy.. 2. 2013
- Prognostic value of the immune microenvironment in lung adenocarcinoma.. 2. 2013
- Trial Watch: Adoptive cell transfer for anticancer immunotherapy.. 2. 2013
- Approaching untargetable tumor-associated antigens with antibodies.. 2. 2013
- Tumor necrosis factor is dispensable for the success of immunogenic anticancer chemotherapy.. 2. 2013
- ATP-dependent recruitment, survival and differentiation of dendritic cell precursors in the tumor bed after anticancer chemotherapy.. 2. 2013
- Trial watch: Oncolytic viruses for cancer therapy.. 2. 2013
- Cancer immunotherapy turns viral.. 2. 2013
- Trial watch: DNA vaccines for cancer therapy.. 2. 2013
- Anti-GD2 antibody 3F8 and barley-derived (1 → 3),(1 → 4)-β-D-glucan: A Phase I study in patients with chemoresistant neuroblastoma.. 2. 2013
- Exploiting the stress response to radiation to sensitize poorly immunogenic tumors to anti-CTLA-4 treatment.. 2. 2013
- Novel multifunctional antibody approved for the treatment of breast cancer.. 2. 2013
- Trial watch: Chemotherapy with immunogenic cell death inducers.. 2. 2013
- Myeloid-derived suppressor sells and the efficacy of CD8+ T-cell immunotherapy.. 2. 2013
- Rejuvenated T cells attack old tumors.. 2. 2013
- Trial watch: Cardiac glycosides and cancer therapy.. 2. 2013
- An anticancer therapy-elicited immunosurveillance system that eliminates tetraploid cells.. 2. 2013
- Trial watch: Monoclonal antibodies in cancer therapy.. 2. 2013
- Victories and deceptions in tumor immunology: Stimuvax®.. 2. 2013
- Anticancer activity of cardiac glycosides: At the frontier between cell-autonomous and immunological effects.. 1. 2012
- How do CARs work?: Early insights from recent clinical studies targeting CD19.. 1. 2012
- Trial watch: Peptide vaccines in cancer therapy.. 1. 2012
- Trial watch: Prognostic and predictive value of the immune infiltrate in cancer.. 1. 2012
- Trial watch: Dendritic cell-based interventions for cancer therapy.. 1. 2012
- "Flagellated" cancer cells propel anti-tumor immunity.. 1. 2012
- Good things come in small packages: Therapeutic anti-tumor immunity induced by microRNA nanoparticles.. 1. 2012
- Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.. 1. 2012
- Trial Watch: Experimental Toll-like receptor agonists for cancer therapy.. 1. 2012
- Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo.. 1. 2012
- Trial Watch: Immunostimulatory cytokines.. 1. 2012
- Loss-of-function alleles of P2RX7 and TLR4 fail to affect the response to chemotherapy in non-small cell lung cancer.. 1. 2012
- Trial Watch: Adoptive cell transfer immunotherapy.. 1. 2012
- Trial watch: Chemotherapy with immunogenic cell death inducers.. 1. 2012
- Trial Watch: Monoclonal antibodies in cancer therapy.. 1. 2012
- Type I interferon induces cancer stem cells-mediated chemotherapy resistance. 2022
- Platinum-based chemotherapy inflames the ovarian carcinoma microenvironment through cellular senescence.. 11. 2022
- Impact of treatment schedule on the efficacy of cytostatic and immunostimulatory agents.. 10. 2021
- NK cells beat T cells at early breast cancer control.. 9. 2020
- Mitochondrial control of innate immune signaling by irradiated cancer cells.. 9. 2020
- Radiation unlocks the therapeutic potential of immune checkpoint blockers in lung cancer patients.. 8. 2019
- Potent immunosuppressive effects of the oncometabolite R-2-hydroxyglutarate.. 7. 2018
- CARs on a highway with roadblocks.. 6. 2017
- Blinatumomab bridges the gap between leukemia and immunity.. 6. 2017
- CD103+ cells at the forefront of anticancer immunity.. 6. 2017
- Soluble NKG2D ligands limit the efficacy of immune checkpoint blockade.. 6. 2017
- PD-L1 blockade for urothelial carcinoma.. 6. 2017
- An epigenetic modifier triggers therapeutic immune responses against breast cancer.. 6. 2017
- Calreticulin and type I interferon: An unsuspected connection.. 6. 2017
- Immunosuppressive γδ T cells foster pancreatic carcinogenesis.. 5. 2016
- Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy?. 4. 2015
- New immunotherapeutic paradigms for castration-resistant prostate cancer.. 2. 2013
- Updates on radiotherapy-immunotherapy combinations: Proceedings of 6th annual ImmunoRad conference. 2023
- Trial watch: intratumoral immunotherapy. 2021
- Activin A backs-up TGF-ß to promote regulatory T cells. 2021
- Trial Watch: experimental TLR7/TLR8 agonists for oncological indications. 2020
- IL15 synergizes with radiotherapy to reprogram the tumor immune contexture through a dendritic cell connection. 2020
- Trial watch: STING agonists in cancer therapy. 2020
- Trial watch: IDO inhibitors in cancer therapy. 2020
- Trial watch: TLR3 agonists in cancer therapy. 2020
- Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology. 2020
- Trial watch: dendritic cell vaccination for cancer immunotherapy. 2019
- Trial watch: dietary interventions for cancer therapy. 2019
- Trial Watch: Toll-like receptor agonists in cancer immunotherapy. 2018
- Trial watch: Peptide-based vaccines in anticancer therapy. 2018
- Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors. 2018
- Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy. 2018
- Trial watch: DNA-based vaccines for oncological indications. 2017
- Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics. 2017
- Trial watch: Immune checkpoint blockers for cancer therapy. 2017
- Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications. 2017
- Trial Watch: Adoptively transferred cells for anticancer immunotherapy. 2017
- Trial watch: Dendritic cell-based anticancer immunotherapy. 2017
- Trial Watch: Immunotherapy plus radiation therapy for oncological indications. 2016
- Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy. 2016
- Prioritization schema for immunotherapy clinical trials in glioblastoma. 2016
- Trial Watch-Immunostimulation with cytokines in cancer therapy. 2015
- Trial Watch-Oncolytic viruses and cancer therapy. 2015
- Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy. 2015
- T cell receptor mimic antibodies for cancer therapy. 2015
- Trial Watch: Adoptive cell transfer for oncological indications. 2015
- Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. 2015
- Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. 2015
- Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. 2015
- Trial Watch: Peptide-based anticancer vaccines. 2015
- Trial watch: Dendritic cell-based anticancer therapy. 2014
- Trial watch: IDO inhibitors in cancer therapy. 2014
- Consensus guidelines for the detection of immunogenic cell death. 2014
- Trial Watch: Radioimmunotherapy for oncological indications. 2014
- Trial Watch:: Oncolytic viruses for cancer therapy. 2014
- Trial Watch: Adoptive cell transfer for anticancer immunotherapy. 2014
- Trial Watch: DNA vaccines for cancer therapy. 2014
- Trial Watch: Chemotherapy with immunogenic cell death inducers. 2014
- Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy. 2014
- Trial Watch: Peptide vaccines in cancer therapy. 2013
- Trial Watch: Lenalidomide-based immunochemotherapy. 2013
- Trial watch: Dendritic cell-based interventions for cancer therapy. 2013
- Trial Watch: Anticancer radioimmunotherapy. 2013
- Trial Watch: Toll-like receptor agonists for cancer therapy. 2013
- Trial Watch: Immunostimulatory cytokines. 2013